MTOR and hepatocellular carcinoma: The reasons for mTOR inhibitor initiation were as follows (in all patients): impaired renal function (n = 17, 20.2%), non-hepatic de novo cancers (n = 7, 8.3%), prevention of HCC recurrence (n = 22, 26.2%), presence of HCC recurrence (n = 23, 27.4%), intolerance to other immunosuppressants (n = 10, 11.9%), and others (n = 5, 6.0%).